<?xml version="1.0"?>
<law>
  <structure>
    <unit label="title" identifier="gcr" order_by="" level="1"/>
    <unit label="chapter" identifier="5-405" order_by="" level="2"/>
  </structure>
  <section_number>gcr-5-405</section_number>
  <catch_line/>
  <text>
    <section prefix="(a)">Schedule IV consists of each controlled dangerous substance:<section prefix="(1)">listed in this section;</section><section prefix="(2)">added to Schedule IV by the Department under &#xA7; 5-202(b) of this title; or</section><section prefix="(3)">designated as a Schedule IV controlled dangerous substance by the federal government unless the Department objects under &#xA7; 5-202(f) of this title.</section></section>
    <section prefix="(b)">Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:<section prefix="(1)">barbital;</section><section prefix="(2)">bromazepam;</section><section prefix="(3)">camazepam;</section><section prefix="(4)">chloral betaine;</section><section prefix="(5)">chloral hydrate;</section><section prefix="(6)">ethchlorvynol;</section><section prefix="(7)">chlordiazepoxide;</section><section prefix="(8)">clobazam;</section><section prefix="(9)">clonazepam;</section><section prefix="(10)">clorazepate;</section><section prefix="(11)">clotiazepam;</section><section prefix="(12)">cloxazolam;</section><section prefix="(13)">delorazepam;</section><section prefix="(14)">diazepam;</section><section prefix="(15)">estazolam;</section><section prefix="(16)">ethinamate;</section><section prefix="(17)">ethylloflazepate;</section><section prefix="(18)">fludiazepam;</section><section prefix="(19)">flunitrazepam;</section><section prefix="(20)">flurazepam;</section><section prefix="(21)">halazepam;</section><section prefix="(22)">haloxazolam;</section><section prefix="(23)">ketazolam;</section><section prefix="(24)">loprazolam;</section><section prefix="(25)">lorazepam;</section><section prefix="(26)">lormetazepam;</section><section prefix="(27)">mebutamate;</section><section prefix="(28)">medazepam;</section><section prefix="(29)">methohexital;</section><section prefix="(30)">meprobamate;</section><section prefix="(31)">methylphenobarbital;</section><section prefix="(32)">nimetazepam;</section><section prefix="(33)">nitrozepam;</section><section prefix="(34)">nordiazepam;</section><section prefix="(35)">oxazepam;</section><section prefix="(36)">oxazolam;</section><section prefix="(37)">paraldehyde;</section><section prefix="(38)">petrichloral;</section><section prefix="(39)">phenobarbital;</section><section prefix="(40)">pinazepam;</section><section prefix="(41)">prazepam;</section><section prefix="(42)">temazepam;</section><section prefix="(43)">tetrazepam; and</section><section prefix="(44)">triazolam.</section></section>
    <section prefix="(c)">Substances listed in Schedule IV include:<section prefix="(1)">a material, compound, mixture, or preparation that contains fenfluramine; and</section><section prefix="(2)">if its existence is possible:<section prefix="(i)">a salt of fenfluramine;</section><section prefix="(ii)">an optical, position, or geometric isomer of fenfluramine; and</section><section prefix="(iii)">a salt of an isomer of fenfluramine.</section></section></section>
    <section prefix="(d)">Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:<section prefix="(1)">diethylpropion;</section><section prefix="(2)">pemoline, including organometallic complexes and their chelates; and</section><section prefix="(3)">phentermine.</section></section>
    <section prefix="(e)">By regulation, the Department may exempt from this section a compound, mixture, or preparation that contains a depressant substance listed in subsection (b) of this section if:<section prefix="(1)">the compound, mixture, or preparation contains an active medicinal ingredient that does not have a depressant effect on the central nervous system; and</section><section prefix="(2)">the admixtures are included in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances that have a depressant effect on the central nervous system.</section></section>
    <section prefix="(f)">The Department may not add a substance to Schedule IV under &#xA7; 5-202 of this title unless the Department finds that:<section prefix="(1)">the substance has a low potential for abuse relative to the substances listed in Schedule III;</section><section prefix="(2)">the substance has currently accepted medical use in treatment in the United States; and</section><section prefix="(3)">abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III.</section></section>
  </text>
</law>
